Ellie Lily‘Blockbuster Drug’moundjaro’ began in India on Thursday. The pharmaceutical manufacturer said that after the approval of Central Drugs Standard Control Organization (CDSCO), it launched the first drug for obesity and type 2 diabetes nationwide. The company said it was introduced As In a single dose vial presentation following CDSCO’s marketing approval.
MOUNJARO is indicated by the initial body mass index (BMI) or 27 kg/m2 or more (27 kg/m2 or more) under the presence of at least one weight -related accompanying conditions. It is the first fixed treatment for obesity, overweight and GIP (glucose-dependent insulin tropic polypeptide) and GLP-1 (glucagon-similar peptide-1) hormonal receptors, overweight and 2 diabetes. “The dual burden of obesity and type 2 is in an important health of India,” said WinSelow Tucker, chairman and governor of Eli Lilly India.
Mounjaro’s introduction is a ray of hope for India, and more than 100 million people are already influenced by diabetes and the main part of the population is obese. Obesity, a chronic recurrent disease, is a major risk factor of diabetes and is associated with more than 200 health complications, including hypertension, abnormal lipidemia, coronary heart disease and obstructive sleep apnea.
MOUNJARO’s introduction to Indian market seems to have a positive impact on the fight against obesity, but be careful about side effects.
Some experts welcomed this drug and talked about side effects. For example, Dr. Keith Siau MOUNJARO’s side effects. “GLP1 receptor agents such as Mounjaro / Ozempic can now be easily purchased without prescription, but be careful of side effects.” He posted on X.
Many users experience camouflage inconvenience, including nausea, vomiting, diarrhea and constipation. Such side effects usually improve over time as the body is adjusted. An appetite loss contributes to weight loss with another common effect, but if it is not properly managed, it can lead to nutritional deficiency.
Some individuals can develop PancreatitisSerious abdominal pain, nausea and vomiting. There is a risk of hypoglycemia (hypoglycemia). Especially when Mounjaro is taken with insulin or other diabetes drugs. Hypoglycemic symptoms include dizziness, sweat, shaking and confusion.
The gallbladder problem, such as gallbladder or gallbladder inflammation, has been reported to some users. Also, as observed in animal studies, there is a potential but rare risk of thyroid tumors. Human research has not confirmed this danger, but people with thyroid cancer troops should pay attention.
Individuals with pancreatitis, thyroid disorders, severe gastrointestinal diseases or gallbladder diseases should consult a doctor before taking Mounjaro. Regular monitoring and lifestyle adjustments can help minimize risks.
Tirzepatide was evaluated in two powerful global clinical development programs: Surmount -1 1 Examination of chronic weight management and advanced tests for chronic weight management and type 2 diabetes.
In Surmount-1, people who take Mounjaro as a weight and weight-related medical problem, including 2,539 adults or diabetes with obesity, diet and exercise, experienced a significant weight loss compared to placebo for 72 weeks. While the mOUNJARO was lost to 21.8 kg in the highest dose (15 mg), the lowest dose (5 mg) on average 15.4kg (compared to 3.2 kg of placebo) 3 losses for 26.3 kg (25%) to 1.5%compared to 1.5%, taking the highest doses of taking mounjaro compared to 1.5%. One in one patient lost an average of 15.4 kg (compared to 3.2 kg in placebo). Error 1,2 In summary, Mounjaro has greatly reduced weight by up to 21.8 kg in Surmount-1.
In a program that surpasses three phases, the efficacy of MOUNJARO 5 mg, 10 mg and 15 mg used together with the usually prescribed diabetes drugs, including metformin, SGLT2 inhibitors, sulponil urea and insulin glazzine, was evaluated. Participants in the ARMPRASS program achieved an average A1C reduction between 1.7% and 2.4% of MOUNJARO 10 mg and MOUNJARO 15 mg for 40 weeks. 3-6 Overall, Mounjaro has been reduced to 2.4%with other diabetes.
“Obesity and diabetes are recognized as serious conditions related to complications of various life limit health, making effective and persistent treatment important. We are pleased to introduce MOUNJARO in order not to meet Mounjaro in India. Dr. Manish Mission, the chief medical officer of Lilly India.
